← Retour à la une
États-Unis · Plateformes & données · Yahoo Finance

Press Release: Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages

Publié par Yahoo Finance · États-Unis il y a 8 h
Sanofi Winthrop Industrie
Sanofi Winthrop Industrie · Yahoo Finance

Résumé détaillé

Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages Paris, November 19, 2026. Sanofi announced today that the European Commission has approved VaxRabeo (rabies virus inactivated strain Wistar) for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) against rabies for all age groups.

Sanofi's next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages

Paris, November 19, 2026. Sanofi announced today that the European Commission has approved VaxRabeo (rabies virus inactivated strain Wistar) for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) against rabies for all age groups. This is the first marketing authorisation approval for VaxRabeo and follows the positive opinion adopted by the European Medicines Agency's Committee for Medicinal Products for Human Use on September 17, 2026.

VaxRabeo is manufactured using state of the art Vero-cell technology. It is formulated to minimize the risk of allergic reactions and has a longer shelf life than current Sanofi rabies vaccines with an improved thermostability.

Rabies is a viral zoonotic disease present in 150 countries, causing approximately 59,000 deaths worldwide annually, according to World Health Organization (WHO) estimates. No treatment exists and it is only preventable by vaccines (in combination with immunoglobulins in post-exposure prophylaxis); once clinical symptoms appear, the disease is almost always fatal. It is transmitted primarily through the saliva of infected animals, most commonly via dog bites, and remains a significant global public health challenge despite being entirely vaccine preventable. According to the WHO, approximately 29 million people receive post-exposure vaccination each year.

"Death from rabies should be prevented at all costs; it is entirely preventable with vaccination provided on time. This first approval of VaxRabeo is a proud milestone for Sanofi and reflects our commitment to rabies protection, built on five decades of expertise and innovation. With VaxRabeo, we are bringing a next-generation rabies vaccine to healthcare systems and patients," said Thomas Triomphe, Head of Vaccines, Sanofi.

The EU approval is supported by a comprehensive clinical programme comparing VaxRabeo with Sanofi's current standard of care vaccines (Verorab…

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

À lire aussi